Role of Endothelium in Doxorubicin-Induced Cardiomyopathy

Authors

Albert Z. Luu, Keenan Research Centre for Biomedical Science
Biswajit Chowdhury, Keenan Research Centre for Biomedical Science
Mohammed Al-Omran, University of Toronto
Hwee Teoh, Keenan Research Centre for Biomedical Science
David A. Hess, University of TorontoFollow
Subodh Verma, Keenan Research Centre for Biomedical Science

Document Type

Article

Publication Date

12-1-2018

Journal

JACC: Basic to Translational Science

Volume

3

Issue

6

First Page

861

Last Page

870

URL with Digital Object Identifier

10.1016/j.jacbts.2018.06.005

Abstract

The clinical use of doxorubicin in cancer is limited by cardiotoxic effects that can lead to heart failure. Whereas earlier work focused on the direct impact of doxorubicin on cardiomyocytes, recent studies have turned to the endothelium, because doxorubicin-damaged endothelial cells can trigger the development and progression of cardiomyopathy by decreasing the release and activity of key endothelial factors and inducing endothelial cell death. Thus, the endothelium represents a novel target for improving the detection, management, and prevention of doxorubicin-induced cardiomyopathy.